News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
How the international nature of science makes him feel at home – The Nobel Prize
Photo taken from The Nobel Prize/LinkedIn
Jan 30, 2024, 14:37

How the international nature of science makes him feel at home – The Nobel Prize

The Nobel Prize posted on LinkedIn:

“”I found my tribe. The tribe of science.”

At our Nobel Week Dialogue on migration, medicine laureate Ardem Patapoutian spoke about how the international nature of science makes him feel at home.

Watch more.”

Source: The Nobel Prize/LinkedIn

Ardem Patapoutian cancer Nobel Week Dialogue OncoDaily Oncology The Nobel Prize The tribe of science
Special Coverage
Career
Jun 1, 2025, 15:07
Mohammad Jad Moussa: A badge of honor to wrap up my postdoc at MD Anderson
Insight
Jun 1, 2025, 14:56
Debra Patt on the Importance of Policy Engagement in Oncology at ASCO 2025
Insight
Jun 1, 2025, 14:52
Key Insights by Tom Powles from ASCO25
Insight
Jun 1, 2025, 14:50
Pashtoon Kasi Highlighted Study on Vilastobart (XTX101) + Atezolizumab in MSS Colorectal Cancer at ASCO 2025
Science
Jun 1, 2025, 14:48
First results of SURE-02 Trial presented at ASCO 2025 by Andrea Necchi
Insight
Jun 1, 2025, 14:41
Aakash Desai: Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025
Blog
Jun 1, 2025, 14:39
Christina Ip-Toma: Integrating germline and tumor genetic results to reduce disparities in cancer care
Blog
Jun 1, 2025, 14:38
Key Insights by Petros Grivas from ASCO25
Science
Jun 1, 2025, 14:38
Kriti Mittal: The ASCO special edition of the ASPIRE CoP newsletter
Oncolibrary
Jun 1, 2025, 13:48
Romiplostim for Chemotherapy-induced Thrombocytopenia Results from global phase iii trial in Gi cancers
Opinion
Jun 1, 2025, 13:42
Efficacy of IL-6R Blockade with Sarilumab in a Quadruple Immuno-Oncology Regimen for Patients with Unresectable Stage III/IV Melanoma
Oncolibrary
Jun 1, 2025, 13:02
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus Ipilimumab Continues to Show Long-Term Survival Benefit in Advanced Renal Cell Carcinoma